RIFM
This article was originally published in The Rose Sheet
Executive Summary
Research Institute for Fragrance Materials "strives to be the international leader for the safe use of fragrance ingredients, and has ongoing research programs in the areas of fragrance allergy, human health effects, respiratory safety and environmental impact," President Ladd Smith states in a letter to the editor of Environmental Health Perspectives published in the November issue of the journal. Smith responds to letter on the toxicity of fragrances by Luke Curtis of the University of Illinois School of Public Health published in June stating the need for more research on the health effects of artificial flavors and fragrances. Vast majority of 4,000 chemicals used in artificial fragrances have not been tested for human toxicity, according to Curtis. Smith, however, points to more recent studies on fragrances and notes RIFM's research is modeled after the National Academy of Sciences' risk assessment method and that research results and safety evaluations are published in peer-reviewed journals...
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.